DM4 Tubulin Inhibitor Payload:
DM4 (CAS: 796073-69-3) is a highly effective antitubulin agent designed to inhibit cell division and disrupt cancer cell growth. This potent compound is crucial in the development of advanced antibody-drug conjugates (ADCs) for targeted cancer therapy.
Key Features
- Mechanism of Action: DM4 inhibits tubulin, disrupting microtubule formation, which blocks mitosis and induces cell death.
- Targeted Therapy: Utilized in ADCs, DM4 is delivered specifically to malignant cells, minimizing harm to healthy tissues and enhancing therapeutic precision.
Applications
- Cancer Treatment: Integral to ADCs, DM4 targets and destroys cancer cells, offering a focused approach to cancer therapy.
- Research and Development: Key in developing new and innovative cancer treatments with reduced side effects.
Advantages
- High Potency: Effective at low concentrations, providing powerful anticancer effects.
- Selective Targeting: Ensures minimal damage to non-cancerous cells, maximizing therapeutic efficacy.
DM4 Tubulin Inhibitor Payload represents a cutting-edge approach to cancer treatment, delivering targeted therapy with precision and reducing collateral damage to healthy tissues. Experience the future of oncology with DM4’s advanced therapeutic capabilities.
Ref:
Fu, Z., Li, S., Han, S. et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Sig Transduct Target Ther 7, 93 (2022).
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
